explore -WSS

explore

author：comprehensive 2025-09-29 17:02:08 - browse：8667

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： FDA sets aggressive timeline for overhauling inspection procedures

leisure time

explore

WSS

Medicare bonuses could stop drug shortages under Senate plan

To bolster infectious disease surveillance, genomics powerhouses team up

Flu vaccine reformulation won't be easy, manufacturers warn

Medicaid rebukes states for mistakenly disenrolling children

Humana sues Biden admin over Medicare Advantage audit rule

A pediatrician calls for Congress to pass the child tax credit deal

entertainment

explore

focus

Walensky prepares to leave CDC — and Congress — behind

Trump surgeon general acknowledges mistakes during Covid

Supreme Court strikes down use of affirmative action

AstraZeneca chief proposes a novel edit to the drug pricing bill

Medical leaders decry Supreme Court decision on affirmative action

Amazon on where the company's health care bets are headed next

At least 13 dead in Texas as scorching temps continue

Medicare bonuses could stop drug shortages under Senate plan

23andMe had bad news about my health. I wish a person had delivered it

Maisha Meds is a PBM, but don't call it that

explore

Immunocompromised patients offer clues on chronic Covid

Covid hospitalizations on the rise, Humana says

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

FDA endorses new sterilization method for medical devices

To bolster infectious disease surveillance, genomics powerhouses team up

What American doctors can learn from their Israeli counterparts

leisure time

explore

leisure time

hotspot